SYRE
Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer.
Spyre Therapeutics, Inc. (SYRE) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D (1.4) | D (1.4) | C+ (2.7) | C+ (2.6) | C- (2.1) |
| 2026-11-08 | C+ (2.5) | D (1.4) | D (1.4) | C+ (2.8) | C+ (2.6) | C- (2.1) |
| 2026-11-01 | C+ (2.5) | D (1.4) | D (1.4) | B- (3.0) | C+ (2.7) | C (2.2) |
| 2026-10-25 | C+ (2.5) | D (1.4) | D (1.4) | B- (2.9) | F (0.0) | D+ (1.6) |
| 2026-10-18 | C+ (2.5) | D (1.4) | D (1.4) | B- (2.9) | F (0.0) | D+ (1.6) |